Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process

Tankel, James; Spicer, Jonathan; Chu, Quincy; Fiset, Pierre Olivier; Kidane, Biniam; Leighl, Natasha B.; Joubert, Philippe; Maziak, Donna; Palma, David; McGuire, Anna; Melosky, Barbara; Snow, Stephanie; Bahig, Houda; Blais, Normand

doi:10.3390/curroncol30120755

Cited by 4 publications

(1 citation statement)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, a current standard of care for the treatment of early-stage NSCLC is to use neoadjuvant chemotherapy and immunotherapy before surgery; however, this approach is reserved for those patients who have tumors with wild-type EGFR and ALK . Hence, delayed biomarker results translate into delays in receiving curative intent surgery [ 26 ]. Timely reporting can also prevent patients from receiving a more toxic and less effective treatment.…”

Section: Molecular Pathology Perspectivementioning

confidence: 99%

Barriers and Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays across Canada

Snow,

Brezden-Masley,

Carter

et al. 2024

Current Oncology

Self Cite

View full text Add to dashboard Cite

Genomic medicine is a powerful tool to improve diagnosis and outcomes for cancer patients by facilitating the delivery of the right drug at the right dose at the right time for the right patient. In 2023, a Canadian conference brought together leaders with expertise in different tumor types. The objective was to identify challenges and opportunities for change in terms of equitable and timely access to biomarker testing and reporting at the education, delivery, laboratory, patient, and health-system levels in Canada. Challenges identified included: limited patient and clinician awareness of genomic medicine options with need for formal education strategies; failure by clinicians to discuss genomic medicine with patients; delays in or no access to hereditary testing; lack of timely reporting of results; intra- and inter-provincial disparities in access; lack of funding for patients to access testing and for laboratories to provide testing; lack of standardized testing; and impact of social determinants of health. Canada must standardize its approach to biomarker testing across the country, with a view to addressing current inequities, and prioritize access to advanced molecular testing to ensure systems are in place to quickly bring innovation and evidence-based treatments to Canadian cancer patients, regardless of their place of residence or socioeconomic status.

show abstract

Section: Molecular Pathology Perspectivementioning

confidence: 99%

Barriers and Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays across Canada

Snow,

Brezden-Masley,

Carter

et al. 2024

Current Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

Lobectomy versus segmentectomy in patients with T1N2 non–small cell lung cancer: An analysis of the National Cancer Database

Iwai,

Tasoudis,

Agala

et al. 2024

JTCVS Open

View full text Add to dashboard Cite

Surgically resectable nonsmall cell lung cancer: a contemporary approach

D'Amours,

Wu,

Theisen-Lauk

et al. 2024

Eur Respir J

View full text Add to dashboard Cite

New treatment paradigms for resectable non-small cell lung cancer (NSCLC), with an emphasis on personalized care and a multidisciplinary approach, have significantly improved patient outcomes. The incorporation of immune checkpoint inhibitors into neoadjuvant, perioperative and adjuvant treatment algorithms is reshaping the standard of care for resectable NSCLC. Adjuvant targeted therapy trials have also paved the way for a much-needed personalized approach for patients with actionable genomic alterations. Innovative surgical techniques and judicious use of post operative radiotherapy may mitigate the toxicity associated with a multimodality approach. Amidst many new treatment options, questions remain about the best approach to consider for each patient. Measurement of minimal residual disease and achievement of pathologic complete response are emerging biomarkers of interest to help further refine treatment selection. This review summarizes the current management of resectable NSCLC, focusing on ongoing and recent advances in surgical approaches, the role of postoperative radiotherapy, and the rapidly changing field of systemic therapies.

show abstract

Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process

Cited by 4 publications

References 114 publications

Barriers and Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays across Canada

Barriers and Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays across Canada

Lobectomy versus segmentectomy in patients with T1N2 non–small cell lung cancer: An analysis of the National Cancer Database

Surgically resectable nonsmall cell lung cancer: a contemporary approach

Contact Info

Product

Resources

About